| Document |
Document Title |
|
WO/2013/039819A2 |
Carbon nanostmctures may be protected and functionalized using a layer-by-layer method whereby functional groups on the carbon nanostmcture surface may be further derivatized to incorporate additional functional moieties. Exemplary moiet...
|
|
WO/2013/039858A2 |
Carbon nanostmctures may be protected and functionalized using a layer-by-layer method whereby functional groups on the carbon nanostmcture surface may be further derivatized to incorporate additional functional moieties. Carbon nanostmc...
|
|
WO/2013/034457A1 |
The invention provides novel lipophilic dopamine derivatives with improved stability and physiological half-life. The compounds may be used for organ and tissue preservation during storage and transport, or in the pre-treatment of organ ...
|
|
WO/2013/035827A1 |
The purpose of the present invention is to provide: a novel compound which is represented by formula (I') and has ACC2 inhibitory activity; and a medicinal composition which contains the compound. (In the formula, R1 represents a substit...
|
|
WO/2013/029648A1 |
A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein: - R' is H or F or trifluoromethyl; - R'' is OH or O-alkyl; - R''' is H or F or trifluoromethyl or phenyl or pyridyl; - R'''' is methylene or acy...
|
|
WO/2013/030358A1 |
The invention relates to 4-aminonaphthalene-2-carboxylic acids and 1-amino- isoquinoline-3-carboxylic acids as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compou...
|
|
WO/2013/033602A2 |
The invention relates to fatty acid amides; compositions comprising an effective amount of a fatty acid amide; and methods for treating or preventing cancer, a metabolic disease or a neurodegenerative disease comprising the administratio...
|
|
WO/2013/032973A1 |
An aromatic amide compound having the following general formula (I) is provided: wherein, X1 and X2 are independently C(O)HN or NHC(O); G1, G2 and G3 are independently hydrogen, C(O)HN-phenyl, or NHC(O)-phenyl, wherein at least one of G1...
|
|
WO/2013/028543A1 |
The disclosure relates to BAX activators and therapeutic uses relates thereto. In certain embodiments, the disclosure relates to methods of treating or preventing cancer, such as lung cancer, comprising administering a therapeutically ef...
|
|
WO/2013/026765A1 |
The present invention relates to novel compounds of formulae (I) and (II) which are useful in the prevention, treatment and diagnosis, in vivo diagnosis of diseases or disorders related to S1P receptors, in particular, in diseases which ...
|
|
WO/2013/028570A2 |
The present invention provides methods of making and using peripherally restricted inhibitors of fatty acid amide hydrolase (FAAH). The present invention provides compounds and compositions that suppress FAAH activity and increases anand...
|
|
WO/2013/022243A2 |
The present invention relates to a novel biphenyl derivative or a pharmaceutically acceptable salt thereof, and relates to a pharmaceutical composition for preventing or treating inflammatory diseases or autoimmune diseases comprising sa...
|
|
WO/2013/022047A1 |
The present invention provides a compound which has an inhibitory activity on lysine-specific demethylase 1 and is useful as a medicinal agent such as a prophylactic or therapeutic agent for cancer and central nervous system diseases. Th...
|
|
WO/2013/019093A2 |
The present invention relates a novel aniline derivatives for anticancer and more particularly, it relates a novel aniline derivatives for anticancer comprising compound of the Formula 1 or a derivative thereof as an active ingredient. A...
|
|
WO/2013/016840A1 |
Disclosed is a novel intermediate used for preparing tapentadol and their analogues, wherein the structure of the intermediate is expressed by formula I or II, and the groups are defined as the description. Also disclosed are the process...
|
|
WO/2013/019635A1 |
The present invention relates to novel retinoid-reiated orphan receptor gamma (RORy) modulators and their use in the treatment of diseases mediated by RORy.
|
|
WO/2013/019091A2 |
Disclosed are a novel compound or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition including the same for inhibiting human 11-β-hydroxy steroid dehydrogenase type 1 (11β-HSD1). The disclosed compound and t...
|
|
WO/2013/019621A1 |
The present invention relates to novel retinoid-related orphan receptor gamma (RORy) modulators and their use in the treatment of diseases mediated by RORy.
|
|
WO/2013/019682A1 |
The present invention relates to novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORy.
|
|
WO/2013/017903A1 |
The invention concerns a new process for the preparation of crystalline form I of agomelatine by freeze-drying.
|
|
WO/2013/017222A1 |
To provide a process for preparing a fatty acid monoalkanolamide, which contains an extremely small amount or substantially no amount of impurities such as ester amines, amide esters, and cyclic amines, without requiring the use of a bas...
|
|
WO/2013/014267A1 |
A process is provided for preparing C8-C22 acyl amido compounds via reaction in a polyol (molecular weight 76 to 300) of interesterifying a fatty acid ester with an amino compound or salt thereof. The resultant mass of material will have...
|
|
WO/2013/016677A1 |
The invention provides well defined N,N-dialkylalkenyl ester compounds for treating glaucoma or ocular hypertension. The esters of the invention are particularly advantageous due to their stability in aqueous solutions.
|
|
WO/2013/014160A1 |
The invention relates to a method for producing carboxylic acid derivatives of general formula (1a): H-(C=0)-R (la), in which R is selected from the group comprising OR1 and NR2R3, wherein R1 is unsubstituted or at least monosubstituted ...
|
|
WO/2013/014354A1 |
The invention relates to ceramide-analogue compounds which have a cyclic structure derived from cyclopropane, from cyclobutane or from cyclopentane, the ring bearing two chains consisting of an amide function. Each amide function is link...
|
|
WO/2013/014265A1 |
A reagent composition for forming fatty acyl amido surfactants is provided which includes an alkali metal or alkaline earth metal salt of an amino compound; a polyol of molecular weight ranging from 76 to 300; and no more than 10% water.
|
|
WO/2013/015440A1 |
Provided is a rubber composition containing: at least one compound selected from among the group comprising a compound represented by formula (I-1), a compound represented by formula (I-2) and a compound represented by formula (I-3); a r...
|
|
WO/2013/014268A1 |
A process is provided for preparing C8-C22 acyl glycinate acid or salt thereof via reacting and heating reacting a mixture of glycine or salt thereof with a fatty acid ester in a medium selected from the group consisting of glycerol, pro...
|
|
WO/2013/010102A2 |
The present invention provides compositions and methods for the administration and targeted delivery, release and/or formation of a drug compound from a halogenated phenol starting compound of the present invention at site(s) within the ...
|
|
WO/2013/004871A1 |
The invention relates to a compound having formula (I) or a stereoisomer, a salt or a solvate, in which: A is -CH(OH)- or -C(=0)-; Z is H or OH; n is 0 or 1; R1 is alkyl(C1-C30), alkenyl(C2-C30) or alkynyl(C2-C30); B is -H, -N3 or -CΞCH...
|
|
WO/2013/005753A1 |
A compound, in which some or all of the hydrogen atoms of the ethylene group constituting propionic acid in 3-[4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl
)carbamoyl]phenyl]propionic acid have been substituted with deuteriu...
|
|
WO/2013/000395A1 |
Disclosed in the present invention is a novel histone deacetylase inhibitor of benzamides and use thereof; the inhibitor has good efficacy in treating diseases caused by abnormal gene expression, such as tumours, endocrine disorders, imm...
|
|
WO/2013/000255A1 |
Disclosed is a use of combination of polyphosphoric acid and metallic zinc, as well as combination of alkali metal salt of halogen anion, polyphosphoric acid and metallic zinc, in decoloring of tetraacetyl ethylene diamine mother liquid....
|
|
WO/2013/000673A1 |
The present invention relates to the use of a compound according to formula (I) in the form of any one of its stereoisomers or a mixture thereof, and wherein n is an integer from 0 to 2; the dotted line represents a carbon-carbon single ...
|
|
WO/2012/177956A1 |
The present invention relates to compounds and pharmaceutical compositions that are useful for treating and/or preventing diabetes or other metabolic diseases, optionally in combination with a second therapy such an active pharmaceutical...
|
|
WO/2012/176830A1 |
Provided are a novel 1,2-bis(dialkylphosphino)-4,5-(methylenedioxy)benzene derivative that forms a metal complex having particularly high asymmetry induction capacity and catalytic activity on β-dehydroamino acids, a method for manufact...
|
|
WO/2012/172387A1 |
The invention concerns a new process for the preparation of two crystalline forms of agomelatine, in particular a process for preparation of form I and a new form of agomelatine, here called form VII.
|
|
WO/2012/173572A1 |
The disclosure provides new methods for the oxidative Heck cross-coupling reaction with electron-rich alkenes such as substituted β-amidoacrylate and other related substituted enamides. Previously, functionalization of enamides under He...
|
|
WO/2012/171114A1 |
Synthetic polyphenolic compounds of formula (I), their modes of synthesis, and pharmaceutical compositions thereof are provided herein. Use of the compounds and compositions described herein for treating cancer and for treating metabolic...
|
|
WO/2012/168665A1 |
The invention relates to an agomelatine cocrystal consisting of: the agomelatine or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide of formula (I); and a solid organic acid.
|
|
WO/2012/166389A1 |
In one aspect, the invention relates to compounds having the formula: (I) where R1, R2, R3, a, R4, R5, and R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition ...
|
|
WO/2012/165651A1 |
A new method for manufacturing a benzylamine compound represented in formula (7) (in the formula, R2 represents a C1-C6 alkyl group optionally having one or more halogen atoms, or a halogen atom, R3 represents a halogen atom or a hydroge...
|
|
WO/2012/165415A1 |
The present invention relates to a method for producing acrylamide by supplying a starting material water to a reactor, supplying acrylonitrile to the reactor, and hydrating the acrylonitrile using a biological catalyst. This method for ...
|
|
WO/2012/165262A1 |
The purpose of the present invention is to provide a novel compound which is effective for the treatment of hematological cancers, particularly multiple myeloma, and is also effective for the inhibition of an SP cell (side population cel...
|
|
WO/2012/167088A1 |
Conjugates of an immune response modifier, a linker, and an antigen are disclosed. The linker is represented by formula (I): wherein A is CH or N, p is in a range from 1 to 50, R" is a bond or -alkylene-O-, R' is alkylene that is optiona...
|
|
WO/2012/162409A1 |
The present invention is directed to biphenyl derivatives of Formula (I), pharmaceutical compositions containing them and their use in the treatment and / or prevention of disorders and conditions ameliorated by antagonizing one or more ...
|
|
WO/2012/157777A1 |
The present invention relates to a method for producing an acrylamide aqueous solution by generating acrylamide by hydrating a composition containing acrylonitrile, wherein the composition containing acrylonitrile contains 20-80 mg of me...
|
|
WO/2012/158122A1 |
The present invention is directed to a method of alkylating a thiol group (R-S-H) or seleno group (R-Se-H) in a target molecule wherein the method comprises: reacting a target molecule comprising at least one thiol group with a compound ...
|
|
WO/2012/155199A1 |
The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the tr...
|
|
WO/2012/157776A1 |
The present invention pertains to an acrylamide aqueous solution containing the proportion of 2-100 mg of 2,2,6,6-tetramethylpiperidine 1-oxyl and 0.2-2.0 mg of manganese ions for every 1 kg of acrylamide. The present invention is able t...
|
